PMID- 18081642
OWN - NLM
STAT- MEDLINE
DCOM- 20080411
LR  - 20071217
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 26 Suppl 2
DP  - 2007 Dec
TI  - Review article: The endoscopic treatment of gastro-oesophageal reflux disease.
PG  - 1-6
LID - 10.1111/j.1365-2036.2007.03473.x [doi]
AB  - BACKGROUND: Over the last 10 years a number of endoscopic procedures for treating 
      gastro-oesophageal reflux disease (GORD) have been developed (suturing, 
      injections, implants and radiofrequency ablation), thus obviating the need for 
      long-term proton pump inhibitors (PPI) and the potential morbidity of 
      laparoscopic fundoplication. AIM: To present an update of the literature studying 
      the clinical efficacy of endoscopic antireflux procedures, and to discuss further 
      developments. METHODS: A PubMed search was performed for endoscopic suturing, 
      antireflux treatment, endoscopic gastroplication, polymer injection, 
      radiofrequency ablation of GORD. Own recent research was compared with existing 
      data. Information concerning GORD endotherapy were gathered. RESULTS: 
      Uncontrolled studies have reported promising clinical results on the short to 
      intermediate term for most endoscopic GORD procedures, but the placebo effect 
      remained unknown. It is, therefore, commendable that the three main procedures 
      (Endocinch, Stretta and Enteryx) have now all been tested against a sham 
      procedure. Although all three techniques were able to improve symptoms, quality 
      of life and PPI use, oesophageal acid reduction was unremarkable. Endocinch and 
      Stretta are safe outpatient procedures. Concerns about the durability of 
      Endocinch have risen. Polymer injection (Enteryx) and gel prosthesis implantation 
      (Gatekeeper) were recalled for severe complications and lack of efficacy, 
      respectively. CONCLUSIONS: Endotherapy has shown the potential to treat 
      (uncomplicated) GORD. However, some early procedures have failed or proven 
      unsafe. Further developments and studies are necessary to determine what 
      modifications to these techniques are required to produce optimal efficacy and 
      durability. Until then, widespread clinical use of endotherapy for GORD should 
      probably be avoided.
FAU - Schwartz, M P
AU  - Schwartz MP
AD  - Department of Gastroenterology, Meander Medical Centre, Amersfoort, The 
      Netherlands. mp.schwartz@meandermc.nl
FAU - Smout, A J P M
AU  - Smout AJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Biocompatible Materials)
SB  - IM
MH  - Biocompatible Materials/*therapeutic use
MH  - Catheter Ablation/standards
MH  - Endoscopy, Digestive System/adverse effects/*methods
MH  - Gastroesophageal Reflux/*surgery
MH  - Humans
MH  - Prostheses and Implants/*standards
MH  - Treatment Outcome
RF  - 31
EDAT- 2008/01/08 09:00
MHDA- 2008/04/12 09:00
CRDT- 2008/01/08 09:00
PHST- 2008/01/08 09:00 [pubmed]
PHST- 2008/04/12 09:00 [medline]
PHST- 2008/01/08 09:00 [entrez]
AID - APT3473 [pii]
AID - 10.1111/j.1365-2036.2007.03473.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:1-6. doi: 
      10.1111/j.1365-2036.2007.03473.x.